Role of developmental immunotoxicity and immune dysfunction in chronic disease and cancer

Area of Science:

• Immunology
• Environmental Health
• Toxicology

Background:

• The developing immune system is highly susceptible to environmental factors, leading to chronic diseases like cancer, asthma, and type 1 diabetes.
• Developmental immunotoxicity (DIT) contributes to significant healthcare costs, drug reliance, and reduced quality of life.
• Current immunotoxicity testing methods are based on an outdated understanding of immune system development and disease etiology.

Purpose of the Study:

• To highlight the inadequacy of current immunotoxicity testing protocols.
• To advocate for mandatory and relevant DIT testing for drugs and chemicals.
• To emphasize the need for protecting pregnant women and children from immune system insults.

Main Methods:

• This study is a critical review of current immunotoxicity testing standards.
• It analyzes the link between early-life immune dysfunction and later-life chronic diseases.
• It examines the limitations of existing safety evaluation protocols for drugs and chemicals.

Main Results:

• Current immunotoxicity testing fails to protect against prevalent immune dysfunction-based pediatric diseases.
• DIT is associated with a spectrum of health risks, including allergies, autoimmune disorders, and cancer.
• Effective drug discovery in immunology contrasts sharply with outdated safety testing.

Conclusions:

• Mandatory DIT testing is crucial for all drugs and chemicals where exposure to pregnant women and children is possible.
• Updated testing protocols are needed to reflect current immunological understanding and disease patterns.
• Implementing relevant DIT testing will improve pediatric health outcomes and reduce long-term healthcare burdens.